Provided by Tiger Trade Technology Pte. Ltd.

Cullinan Therapeutics

20.54
+0.14000.69%
Post-market: 20.30-0.2357-1.15%19:30 EDT
Volume:1.06M
Turnover:21.53M
Market Cap:1.32B
PE:-5.92
High:20.71
Open:20.38
Low:19.64
Close:20.40
52wk High:23.19
52wk Low:5.68
Shares:64.35M
Float Shares:48.08M
Volume Ratio:0.96
T/O Rate:2.21%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4680
EPS(LYR):-3.7236
ROE:-50.30%
ROA:-31.36%
PB:4.11
PE(LYR):-5.52

Loading ...

Cullinan Therapeutics price target raised to $46 from $33 at Clear Street

TIPRANKS
·
Jun 11

BUZZ-U.S. STOCKS ON THE MOVE-Illumina, Cullinan, BorgWarner

Reuters
·
Jun 11

Analysts’ Top Healthcare Picks: Dianthus Therapeutics (DNTH), Cullinan Management (CGEM)

TIPRANKS
·
Jun 11

BUZZ-Cullinan rises as early-stage data show remission in autoimmune disease drugs

Reuters
·
Jun 10

Cullinan Therapeutics releases Immunology Day presentation

Reuters
·
Jun 10

Cullinan Therapeutics Reports Early Positive Autoimmune Drug Data, Plans Next Trial Steps

MT Newswires Live
·
Jun 10

Cullinan Therapeutics Highlights Positive Early Autoimmune Trial Data

TIPRANKS
·
Jun 10

Cullinan Therapeutics reports CLN-978, velinotamig data

TIPRANKS
·
Jun 10

Cullinan shares Phase 1 data showing CLN-978 induces remission in difficult-to-treat rheumatoid arthritis patients

Reuters
·
Jun 10

Cullinan: Sees Additional Multi-Dose Data for Cln-978 in Ra Next Quarter and in Sle in Q4, Additional Data for Velinotamig Before End of Year

THOMSON REUTERS
·
Jun 10

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting Cd19 and Bcma in Autoimmune Diseases

THOMSON REUTERS
·
Jun 10

Cullinan Therapeutics Inc: Cln-978 (Cd19 Tce) Eular Data Demonstrated Potential for Immune Reset, Including Remissions, in Both Sle and Ra

THOMSON REUTERS
·
Jun 10

Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases

GlobeNewswire
·
Jun 10

Cullinan Showcases Promising CLN-978 Phase 1 Autoimmune Data

TIPRANKS
·
Jun 08

Analysts Offer Insights on Healthcare Companies: Praxis Precision Medicines (PRAX), Amylyx Pharmaceuticals Inc (AMLX) and Cullinan Management (CGEM)

TIPRANKS
·
Jun 08

Cullinan Therapeutics Shares Rise on Positive Early Trial Data for Autoimmune Drug

Dow Jones
·
Jun 08

Cullinan Therapeutics Price Target Maintained With a $30.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 08

Analysts Conflicted on These Healthcare Names: Cullinan Management (CGEM) and Pfizer (PFE)

TIPRANKS
·
Jun 08

Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), GMR Solutions, Inc. Class A (GMRS) and Cullinan Management (CGEM)

TIPRANKS
·
Jun 08

Cullinan Therapeutics presents clinical data for CLN-978

TIPRANKS
·
Jun 08